Table 1.
Patient demographics
| New diagnosis (n=133) | Relapse (n=151) | ||
|---|---|---|---|
| Sex | |||
| Male | 69 (52%) | 61 (40%) | |
| Female | 64 (48%) | 90 (60%) | |
| Age (years) | |||
| 16–25 | 49 (37%) | 46 (30%) | |
| 26–35 | 32 (24%) | 36 (24%) | |
| 36–45 | 18 (14%) | 28 (19%) | |
| >45 | 34 (26%) | 41 (27%) | |
| Disease duration (years) | |||
| <1 | NA | 5 (3%) | |
| 1–5 | NA | 45 (30%) | |
| 6–10 | NA | 39 (26%) | |
| >10 | NA | 62 (41%) | |
| Disease location (Montreal classification)* | |||
| L1 | NA | 56 (37%) | |
| L2 | NA | 17 (11%) | |
| L3 | NA | 74 (49%) | |
| L4 | NA | 4 (3%) | |
| Disease behaviour (Montreal classification)* | |||
| B1 | NA | 80 (53%) | |
| B1p | NA | 4 (3%) | |
| B2 | NA | 52 (34%) | |
| B2p | NA | 1 (1%) | |
| B3 | NA | 12 (8%) | |
| B3p | NA | 2 (1%) | |
| Medication† | |||
| None | 62 (47%) | 32 (21%) | |
| Mesalazine | 21 (16%) | 26 (17%) | |
| Steroids | 48 (36%) | 28 (19%) | |
| Immunomodulators | 16 (12%) | 75 (50%) | |
| Anti-TNF antibodies | 5 (4%) | 42 (28%) | |
| Previous enteric resection | 1 (1%)‡ | 72 (48%) | |
Data are n (%). TNF=tumour necrosis factor. NA=not applicable.
*
Montreal classification not collected for patients in the new diagnosis group.
†
Patients could take more than one type of medication.
‡
Surgical resection for inflammatory mass 1 year before Crohn's disease diagnosis.